Purpose: Systemic delivery of messenger RNA-based therapeutics remains a challenging issue for preclinical and clinical studies. This study is to develop lipid-like nanoparticles for mRNA delivery in vivo. 
1
Methods: We applied an orthogonal experimental design, which is a well-established approach for biomedical studies. [2] [3] [4] [5] This approach enables us to fine-tune the formulation ratios with a minimum number of experiments. We investigated four levels for each formulation component: TT3, DOPE, cholesterol, and DMG-PEG2000. Theoretically, four levels of four formulation components can give 256 combinations. By utilizing the orthogonal experimental design, we were able to evaluate the effects of the four components with only 16 combinations.
Results:
We have developed a new type of lipid-like compounds N 1 ,N 3 ,N 5 -tris(2-aminoethyl)benzene-1,3,5-tricarboxamide derivatives, composed of a phenyl ring, three amide linkers, and three amino lipid chains. An orthogonal experimental design enables us to improve the delivery efficiency of TT3 lipid-like nanoparticles (TT3 LLNs, Figure 1 ) over 350-fold with significantly reduced experimental workload. Our correlation analysis indicates that entrapment efficiency of mRNA plays a key role for cellular transfection. Zeta potential may correlate with mRNA delivery efficiency for certain LLNs formulations. Consistent with reports in the literature, 6 we show that PEGylation of TT3 LLNs improved particle stability and reduced particle size, but hindered delivery efficiency. After the ratio of DMG-PEG 2000 was optimized, O-TT3 LLNs showed over 110-fold higher delivery efficiency compared to the start-point TT3-DSPC LLNs, and O-TT3 LLNs were stable for over two weeks. Moreover, O-TT3 LLNs showed much higher delivery efficiency of Fluc mRNA both in vitro and in vivo, compared to a C12-200-DSPC LLNs reported previously. Most importantly, O-TT3 LLNs are capable of producing a therapeutically relevant level of hFIX in both wild-type and FIX-knockout mice. 
Conclusions:
We have developed new lipid-like nanoparticles (TT-LLNs) through an orthogonal array design, which has improved delivery efficiency of mRNA encoding luciferase in vitro by over 350-fold with significantly reduced experiment workload. One lead material, O-TT3 LLNs, was able to produce a therapeutically relevant level of human factor IX (hFIX) in both wild-type and FIX-knockout mice. Consequently, these mRNA based nanomaterials merit further development of therapeutic applications.
